Drg Stimulator denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for drg stimulator are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied a Dorsal Root Ganglion Stimulator as Non-Formulary

Although "formulary" language is most commonly associated with drug coverage, BCBS and other insurers apply similar tiered-coverage structures to implantable devices and procedures. A "non-formulary" denial for a DRG stimulator typically means the specific device brand or model has not been approved under BCBS's preferred vendor or contracted device list, or that the procedure falls outside a preferred network or facility tier. This is a coverage-tier issue, distinct from a medical-necessity or experimental denial.

## Why This Is Appealable

Non-formulary or non-preferred device denials are appealable on two grounds: (1) a formulary exception based on medical necessity — demonstrating that a preferred alternative is clinically inferior or inappropriate for this patient; or (2) a network/contracting issue that can sometimes be resolved by identifying a contracted provider who uses a covered device. Your appeal should clarify which ground applies and pursue both if relevant.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial. Request from BCBS the specific reason the device or vendor is non-formulary and whether a formulary exception process exists.
• External review (ACA §2719): If the internal appeal is denied, request independent external review within 4 months. The IRO reviews without deference to BCBS's formulary decisions.
• ERISA §503 (self-funded plans): Full-and-fair review rights apply.
• Network adequacy: If no in-network provider offers a covered device, BCBS may be required to authorize an out-of-network provider at in-network cost-sharing under network adequacy rules — check your state's requirements.

## Documentation to Gather

1. Identification of the denied device — the exact brand, model, and manufacturer of the DRG stimulator that was requested. 2. BCBS's preferred/formulary device list — obtained from BCBS to identify which devices are covered and which providers are contracted to implant them. 3. Clinical rationale for the requested device — if a preferred device exists, a physician letter explaining why the preferred device is clinically inadequate or inappropriate for this patient. 4. Diagnosis and treatment history — supporting documentation demonstrating medical necessity for DRG stimulation generally. 5. Network adequacy check — documentation of whether any in-network provider offers the covered device within a reasonable geographic distance.

## Criteria-Mapping Structure

| Non-Formulary Exception Criterion | Your Documentation | |---|---| | Requested device identified | [Device name, model, manufacturer] | | Preferred alternative identified | [BCBS formulary device] | | Clinical reason preferred alternative is unsuitable | [Physician letter] | | Medical necessity for DRG stimulation generally | [Diagnosis and treatment history] | | Network adequacy concern (if applicable) | [Provider search documentation] |